

Contents

Summary.....	1
1 Introduction	2
1.1 Alzheimer's disease.....	2
1.2 Cholinergic hypothesis	2
1.3 Approaches for treatment of AD's	2
1.4 Cholinergic enhancement therapy	3
1.5 Structure of AChE.....	4
1.6 Overview of the three-dimensional structure of AChE.....	4
1.6.1 The active center and the catalytic triad.....	5
1.6.2 Peripheral anionic site	6
1.6.3 Acylation of ACh within the binding pocket	7
1.7 Acetylcholinesterase inhibitors (AChEI)	8
1.7.1 Synaptic cholinergic drugs	8
1.7.2 Pseudo-irreversible AChEIs	9
1.7.3 Irreversible AChEIs.....	10
1.7.4 Transition state analogue inhibitors	10
1.7.5 Reversible AChEIs	10
1.8 Protein-Ligand docking.....	14
1.8.1 General procedure of docking	14
1.8.2 Docking Algorithms implemented in this collection	15
! Description of the consensus molecular docking approach	19
2.1 The initial requirements	19
2.2 Characteristic features of the consensus method.....	19
2.2.1 Aim of the consensus method	20
2.2.2 Multi-Step Docking (MSD) procedure	21
2.3 Application of MSD method for bound docking BHG	22
2.4 Study on the importance of data filtration by bound docking of BHG	26
2.5 Unbound docking study on BHG	28
2.6 Importance of selection a suitable protein for unbound docking	31
2.7 A comparison of unbound docking using simulated annealing with using MSD	33

2.8	Comparison of the MSD result with various other docking methods	35
3	Evaluation of MSD	37
3.1	Application of MSD for elucidation of structural properties of (BHG).....	37
3.2	Bound docking experiment on BHG-AChE complex.....	38
3.3	Bound docking of BHG into binding site with waters	39
3.4	Docking study on E2020	45
3.4.1	Study on the configuration state of the molecule at C8	45
3.4.2	Study on the protonation state at E2020-Nitrogen	46
3.4.3	Effect of the environment on the conformational pose of E2020	47
3.4.4	Unbound docking study on E2020	48
3.5	Study on Decamethonium (DECA).....	50
3.5.1	Bound docking study on Decamethonium (DECA).....	50
3.5.2	Docking decamethonium into the empty binding site of 1ACL	50
3.5.3	Docking decamethonium into the binding site of 1ACL including waters.....	51
3.5.4	Unbound docking study on decamethonium (DECA)	53
3.6	Application of MSD for bound docking study on several inhibitors of other proteins than AChE	54
3.6.1	Bound docking of Win51711 and Win52084	54
3.6.2	Unbound docking study on Deoxythymidine.....	56
3.6.3	Bound docking study of oxindole	57
4	Elucidation of structural properties of (PPG).....	59
4.1	Searching for the protonation state of PPG using bound docking	60
4.2	Conformation at galanthamine and piperidine substructures by unbound docking study	65
4.3	Unbound docking of PPG protonated at the galanthamine-nitrogen (N10).....	66
4.4	Unbound docking of PPG protonated at the piperidine-nitrogen (N22)	67
5	Molecular docking studies on the “Back Door” hypothesis	71
5.1	Docking study on protonation of DMPO	73
5.1.1	MSD method	73
5.1.2	G.O.L.D	75
5.2	Study on the location of leaving group in the absence of DMPO.....	78
5.3	Study on the location of leaving group in presence of DMPO	79

5.3.1	MSD method	79
5.3.2	G.O.L.D.....	81
5.4	Docking experiment on eseroline in presence of waters	83
5.5	Simulated annealing	Error! Bookmark not defined.
6	Binding mode prediction of galanthamine derivatives using MSD ...	87
6.1	Binding mode prediction of bisgalanthamide analogues into AChE binding site ...	87
6.2	Binding mode prediction of (IHG) into AChE binding site.....	89
6.3	Docking IHG in binding site of 1EVE	90
7	References	93
8	Abbreviations	91
	Curriculum vitae	98